Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

£240m Investment Committed

Executive Summary

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

You may also be interested in...



More Candidate COVID-19 Vaccines Expected To Enter WHO’s Global Trial

A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.

UK Vaccines Business Pushes Wockhardt To Sales Growth

Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel